Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Protein tyrosine phosphatase PTP-1B inhibitors under study at Roche

Jan. 21, 2005

Phase II trial investigates alagebrium chloride for erectile dysfunction

Jan. 21, 2005

DPP-IV inhibitor PSN-9301 enters phase II study

Jan. 21, 2005

GFAT inhibitors for type 2 diabetes disclosed in patent

Jan. 20, 2005

Pivotal phase III study of Bio-E-Gel completes enrollment

Jan. 20, 2005

Potential oxazolidine candidate for the treatment of diabetes

Jan. 20, 2005

New data on the pharmacokinetics and pharmacodynamics of oral insulin spray

Jan. 19, 2005

Evidence suggests an association between resistin and insulin resistance in humans

Jan. 19, 2005

Arimoclomol shows potential for type 2 diabetes in rat studies

Jan. 19, 2005

Similar efficacy found for darbepoetin alfa and epoetin alfa in chemotherapy-induced anemia

Jan. 19, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....